Lysin based novel antibacterial proteins
| Reference number | |
| Coordinator | Novalysin AB - Kemicentrum |
| Funding from Vinnova | SEK 300 000 |
| Project duration | July 2020 - February 2021 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovative Startups step 1 spring 2020 |
Important results from the project
The aim of the project was to verify antibacterial effect and to develop a business model. The goal and objectives of the project have been fulfilled: The selected lysin based products were produced and purified in small scale, and their antibacterial activity against mycobacteria was verified A differentiated business model has been proposed and two product lines are planned to be developed (1) a drug product against TB that will be marketed via collaborative commercialization, and (2) a medical device product.
Expected long term effects
The purified lysin based products demonstrated antimycobacterial activity. A patent application has been filed. No competitors were identified in this technology area. We note protein production in large amounts to be a challenge and we are developing different solutions for this. We have noted great interest in our products as a sustainable alternative to antibiotics.
Approach and implementation
The activities in the project were divided into two parts technical and business model development. Successful protein production was achieved in small scale after screening and optimization of experimental conditions. The antibacterial activity of the purified proteins was verified, and candidates for further development are selected. We have performed a preliminary market survey, identified competitors as well as partners for formulation and clinical tests, and calculated needed investment.